Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isopropamide is a long-acting quaternary ammonium anticholinergic (antimuscarinic) drug. It acts as an antagonist at muscarinic acetylcholine receptors, particularly the M3 subtype, thereby inhibiting the action of acetylcholine on smooth muscle and glandular tissue. This results in reduced gastrointestinal motility and secretion. Isopropamide was discovered by Janssen Pharmaceutica in 1954 and has been used primarily for the treatment of peptic ulcers and other gastrointestinal disorders characterized by hyperacidity or hypermotility, such as irritable bowel syndrome and nervous dyspepsia. It may also be used to relieve symptoms associated with colds or rhinitis due to its peripheral antimuscarinic effects similar to those of atropine[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Isopropamide.